PULIKE(SH:603566) Shang Hai Zheng Quan Bao·2025-09-29 21:55Core Viewpoint - The company has received a new veterinary drug registration certificate for a combined vaccine targeting three major viral diseases in cats, which is expected to enhance its product offerings and market competitiveness in the pet healthcare sector [1][5]. Group 1: New Veterinary Drug Information - The new veterinary drug is a combined inactivated vaccine for feline panleukopenia, feline calicivirus, and feline herpesvirus type 1, with specific viral strains included [1]. - The vaccine is classified as a Class III veterinary drug and contains specific viral loads per dose, ensuring effective immunization [1]. - The vaccine is intended for subcutaneous injection in healthy cats aged 8 weeks and older, with a primary dose followed by annual boosters [2]. Group 2: Research and Development Background - The development of the new vaccine involved a total investment of 8.03 million yuan in research and development [3]. - The targeted viruses are among the most prevalent and harmful to domestic and wild feline populations, highlighting the vaccine's importance in disease prevention [3]. - The vaccine boasts several advantages, including high immunogenicity, prolonged immunity duration of at least 12 months, reduced side effects, and stable production quality [3]. Group 3: Market Context - Currently, there is one imported vaccine and one domestic vaccine that have received registration and are available in the market, along with ten domestic vaccines that have received temporary approval [3]. - The successful development of this new vaccine reflects the company's commitment to innovation and strengthens its position in the pet vaccine market [5]. Group 4: Regulatory Requirements - Before the vaccine can be marketed, it must obtain a veterinary product approval number from the Ministry of Agriculture and Rural Affairs [4]. Group 5: Impact on the Company - The acquisition of the new veterinary drug certificate is expected to drive performance growth for the company, enhance its product competitiveness, and support disease prevention in pets [5].